Skip to main content
. 2015 Dec 14;5:18215. doi: 10.1038/srep18215

Figure 1. Akbu-LAAO inhibits the in vitro proliferation of HepG2.

Figure 1

(A) MTT assay indicated Akbu-LAAO treatment for 24 h dose-dependently inhibited HepG2 proliferation. (B) The administration of 38.82 μg/mL Akbu-LAAO time-dependently inhibited HepG2 growth. (C) BrdU assay showed Akbu-LAAO treatment for 24 h dose-dependently inhibited HepG2 proliferation.